William N. Hait, MD, PhD
Global Head, Janssen Research & Development, Raritan, New Jersey
As an internationally recognized expert in translational cancer research, Dr. Hait has sought to integrate molecular and cellular biology with clinical pharmacology, and translate findings to the clinic. His research has a special focus on multidrug resistance in breast cancer and the mechanisms of drug resistance in other cancers.
Dr. Hait is a master clinician/pharmacologist and has served on numerous scientific advisory committees for industry, academia and the private sector. He was the founding director of the Cancer Institute of New Jersey and built that organization in less than nine years from a three-person operation to become a comprehensive cancer center.
2010-present Treasurer, AACR2007-2011 Senior Vice President and Therapeutic Area Head, Hematology/Oncology Research and Development, Johnson & Johnson2007-2008 President, AACR2006 Edward J. Ill Physician’s Award2005-2007 Editor-in-Chief, Clinical Cancer Research2003 The American Jewish Congress Maimonides Award2000 Thomas Edison Award of Excellence1998 Person of the Year Award, New Jersey Medicine1994-2007 Associate Dean for Oncology Programs, UMDNJ-Robert Wood Johnson Medical School1993-2007 Director, The Cancer Institute of New Jersey1993-2007 Professor of Medicine and Pharmacology, UMDNJ Robert Wood Johnson Medical School1988-1992 Chief, Section of Medical Oncology, Yale University School of Medicine1987-1992 Director, Breast Cancer Unit, Yale University School of Medicine1986-1992 Associate Director, Yale University Comprehensive Cancer Center1978 MD, PhD Medical College of Pennsylvania (Drexel College of Medicine)